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Background: Phase I of the International Study of Asthma and Allergies in Childhood (ISAAC) was designed
to allow worldwide comparisons of the prevalence of asthma symptoms. In phase III the phase I survey was
repeated in order to assess changes over time.
Methods: The phase I survey was repeated after an interval of 5–10 years in 106 centres in 56 countries in
children aged 13–14 years (n = 304 679) and in 66 centres in 37 countries in children aged 6–7 years
(n = 193 404).
Results: The mean symptom prevalence of current wheeze in the last 12 months changed slightly from 13.2%
to 13.7% in the 13–14 year age group (mean increase of 0.06% per year) and from 11.1% to 11.6% in the
6–7 year age group (mean increase of 0.13% per year). There was also little change in the mean symptom
prevalence of severe asthma or the symptom prevalence measured with the asthma video questionnaire.
However, the time trends in asthma symptom prevalence showed different regional patterns. In Western
Europe, current wheeze decreased by 0.07% per year in children aged 13–14 years but increased by 0.20%
per year in children aged 6–7 years. The corresponding findings per year for the other regions in children
aged 13–14 years and 6–7 years, respectively, were: Oceania (20.39% and 20.21%); Latin America
(+0.32% and +0.07%); Northern and Eastern Europe (+0.26% and +0.05%); Africa (+0.16% and +0.10%);
North America (+0.12% and +0.32%); Eastern Mediterranean (20.10% and +0.79%); Asia-Pacific (+0.07%
and20.06%); and the Indian subcontinent (+0.02% and +0.06%). There was a particularly marked reduction
in current asthma symptom prevalence in English language countries (20.51% and 20.09%). Similar
patterns were observed for symptoms of severe asthma. However, the percentage of children reported to have
had asthma at some time in their lives increased by 0.28% per year in the 13–14 year age group and by
0.18% per year in the 6–7 year age group.
Conclusions: These findings indicate that international differences in asthma symptom prevalence have
reduced, particularly in the 13–14 year age group, with decreases in prevalence in English speaking
countries and Western Europe and increases in prevalence in regions where prevalence was previously low.
Although there was little change in the overall prevalence of current wheeze, the percentage of children
reported to have had asthma increased significantly, possibly reflecting greater awareness of this condition
and/or changes in diagnostic practice. The increases in asthma symptom prevalence in Africa, Latin America
and parts of Asia indicate that the global burden of asthma is continuing to rise, but the global prevalence
differences are lessening.
T
he International Study of Asthma and Allergies in
Childhood (ISAAC) was founded to maximise the value
of epidemiological research into asthma, allergic rhinocon-
junctivitis and eczema through facilitating international colla-
boration.1–4 Although epidemiological research has the potential
to add to our understanding of these conditions, previous
studies have lacked standardisation in case definition and
methodology, thus limiting the value of spatial and temporal
comparisons of the prevalence of these disorders. The ISAAC
programme was designed to allow comparisons of the
prevalence of these disorders between populations in different
countries and their trends over time,1 2 since these may be
particularly informative in suggesting hypotheses about the
causes of the observed patterns and hence about the causes of
asthma, rhinitis and eczema.
In phase I, children aged 13–14 years were studied in 155
centres in 56 countries (n = 463 801) and children aged 6–
7 years were studied in 91 centres in 38 countries
(n = 257 800).5–8 Up to 20-fold variations in the prevalence of
‘‘current wheeze’’ (in the last 12 months) were observed
between centres worldwide (range 1.8–36.7%), with a sevenfold
variation observed between the 10th and 90th percentiles
(4.4%, 30.9%). The highest 12 month period prevalences were
from centres in the UK, Australia, New Zealand and the
Republic of Ireland, followed by some centres from North,
Central and South America; the lowest prevalences were from
centres in Eastern Europe, Albania, Greece, China, Taiwan,
Uzbekistan, India, Indonesia and Ethiopia. Phase II involved
more intensive investigation of possible aetiological factors in
9–11-year-old children in 30 centres in 22 countries.9
Phase III has involved repeating the phase I survey after 5–
10 years to: (1) examine time trends in the prevalence of
asthma, allergic rhinoconjunctivitis and eczema in centres and
countries which participated in phase I; (2) describe the
prevalence and severity of asthma, allergic rhinoconjunctivitis
and eczema in centres and countries which are of interest but
did not participate in phase I; and (3) examine hypotheses at an
individual level which have been suggested by the findings of
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phase I, subsequent ecological analyses and recent advances in
knowledge. An overview of the findings for time trends for
symptoms of all three conditions in those centres that
participated in both phase I and phase III (ie, objective (1)
above) has been presented in a previous publication.10 That
publication only included the findings for ‘‘current wheeze’’,
whereas the current paper uses each of the seven ISAAC
questions to describe the detailed findings for time trends in the
prevalence of asthma symptoms.
METHODS
Phase III was conducted following as precisely as possible the
methods used in phase I.2 3 It included two groups of centres:
(1) Group A are centres that previously completed phase I
according to the ISAAC phase I protocol, including centres for
which the phase I data were submitted too late for inclusion in
the first worldwide publications but were of the required
standard; (2) Group B are centres from around the world that
did not participate in phase I but participated in phase III as
new centres. The analysis of time trends presented here is
necessarily confined to the Group A centres, and we will
therefore focus on them in describing the methods.
Group A centres were required to conduct phase III in the
same way as phase I following, as precisely as possible, the
details of the centre methodology documented in the phase I
centre report. Each principal investigator was sent a final copy
of the phase I centre report from the ISAAC International Data
Centre (IIDC). They were then required to use the same
sampling frame (the exact same set of schools was not aimed
for but some schools were reselected by the random sampling
process), age groups, sample size, method of choosing the
children, the same symptom questionnaires (plus an environ-
mental module), the same translations (if applicable) and the
same time of year for data collection. Thus, as in phase I, the
written questionnaire and video questionnaires were self-
completed in the 13–14 year age group whereas the written
questionnaire was completed by a parent for children in the 6–
7 year age group.
The Steering Committee required documentation of the
procedures for the study from each centre as a prerequisite
for inclusion in publications of ISAAC worldwide results.
Centres completed a registration document before starting the
study and followed the published ISAAC phase III manual and
ISAAC coding and data transfer manual. The phase III data and
centre report submitted to the IIDC were checked for coding
errors, omissions and inconsistencies and these were corrected
with the assistance of the collaborator.
As in phase I, the 6–7 year and 13–14 year age groups were
analysed separately. Symptom prevalences in each centre were
calculated by dividing the number of positive responses to each
question by the number of completed questionnaires for the
written and video questionnaires separately. Thus, apparent
inconsistencies between responses to the stem and branch
questions were accepted and not recoded. For each centre the
annual change in symptom prevalence was calculated by taking
the difference between the phase I and phase III prevalences
and dividing by the number of years between the two surveys.
The findings for the question on ‘‘current wheeze’’ have
previously been published10 but are also included in the current
paper, together with the findings for the other asthma
symptom questions, in order that the findings and patterns
for current wheeze, severe asthma symptoms and diagnosed
asthma can be compared and contrasted.
The data are presented in tabular form with the phase III
prevalence and the annual change in prevalence for each
question. For the regional and global summaries, the data for
each centre were weighted by the inverse of the variance of the
change. The regional analyses were based on the standard
ISAAC regions, but we also performed analyses specifically for
English language countries (Australia, Canada, Channel
Islands, Isle of Man, New Zealand, Republic of Ireland, UK,
USA). The findings were generally very similar in males and
females; for example, the global change in the prevalence of
‘‘current wheeze’’ in children aged 13–14 years was 0.05% per
year in males and 0.07% per year in females, and males and
females also showed similar time trends in most regions. We
have therefore presented only the overall findings (both sexes
combined). The key findings were also presented as ‘‘ranking
plots’’ showing the change in prevalence of a symptom (such as
current wheeze) for each centre by country, with countries
ordered by their mean prevalence (for all centres combined)
across phase I and phase III. The mean prevalence (rather than
the phase I prevalence) was used to order countries since this is
statistically independent from the change in prevalence
(between phases I and III) whereas the phase I prevalence is
not.11–13 The ranking plot also shows the confidence interval
about zero change for a given level of prevalence (ie, the mean
prevalence across phases I and III), given a sample size of 3000
and assuming no cluster sampling effect.
RESULTS
Participants
The details of the participating centres are listed in a separate
phase III overview paper.10 Phase I involved 155 collaborating
centres in 56 countries for the 13–14 year age group with a total
of 463 801 participating children. The video questionnaire was
completed in 99 collaborating centres in 42 countries with a
total of 304 796 children. For children aged 6–7 years there
were 91 collaborating centres in 38 countries with a total of
257 800 participating children. Of the centres that participated
in phase I, 106 centres in 56 countries completed the phase III
survey and met the requirements for analysis, with a total of
304 679 participating children in the 13–14 year age group
(overall response rate 91%);10 54 centres in 32 countries (a total
of 167 513 children) also completed the video questionnaires in
this age group. Sixty-six centres in 37 countries, a total of
193 404 children (response rate 85%)10 completed the survey
and met the requirements for analysis in the 6–7 year age
group. Four of the centres only did the survey in children aged
6–7 years so, in total, there were 110 centres (in either age
group) in 58 countries.
13–14 year age group
Written questionnaires
The changes from phase I for symptoms of asthma (with the
phase III prevalence rates in parentheses) in 13–14-year-old
children are summarised by region in table 1 (the detailed
findings by centre and country are summarised in web table 1
available online at http://thorax.bmj.com/supplemental). The
mean prevalence of ‘‘current wheeze’’ (‘‘Have you had
wheezing or whistling in your chest in the past 12 months?)
increased only slightly from 13.2% to 13.7% (a mean increase of
0.06% per year). There was also little change in the mean
prevalence of symptoms of severe asthma. However, the
changes in asthma symptom prevalence showed different
regional patterns with current wheeze decreasing in those
regions such as Oceania (20.39% per year) that had previously
shown the highest rates; there was a particularly marked
reduction in the prevalence in English language countries
(20.51% per year). In Latin America, which had also previously
shown relatively high rates, the prevalence increased (+0.32%
per year). It also increased in regions such as Northern and
Eastern Europe (+0.26% per year), Africa (+0.16% per year) and
North America (+0.12% per year). There was little change in the
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Asia-Pacific region (+0.07% per year) and the Indian sub-
continent (+0.02% per year), and a small decrease in the
Eastern Mediterranean (20.10% per year) and Western Europe
(20.07% per year).
Figure 1 gives the ranking plot showing the change in
prevalence of current wheeze for each centre by country, with
countries ordered by their average prevalence (for all centres
combined) across phase I and phase III. It shows that, in
general, the countries with the highest prevalence in phase I
(including most of the English language countries) showed
decreases in prevalence between phase I and phase III, whereas
some of the countries which had previously had low prevalence
showed increases. However, there were a number of countries
(eg, India, Albania) which had very low prevalence in phase I
and little increase in phase III.
Figure 2 shows the corresponding ranking plot for severe
asthma, as measured by >4 attacks of wheezing in the previous
12 months. It generally shows similar patterns to those for
current wheeze, with decreases in prevalence in English
language countries and increases in prevalence in some, but
not all, of the countries that had low prevalence in phase I.
In contrast to the findings for current wheeze, the percentage of
children reported to have had asthma at some time in their lives
increased from 11.2% to 13.8% in the 13–14 year age group, an
annual increase of 0.28% per year (table 1 and fig 3). There were
particularly large increases in Oceania (+0.93% per year), Western
Europe (+0.33% per year) and North America (+0.71% per year),
despite the fact that these regions showed little change (or even a
reduction) in symptom prevalence. The average proportion of
children with ‘‘current wheeze’’ who were reported to have had
asthma at some time in their lives increased only from 43% to
46%, but there were larger increases in Oceania (54% to 64%),
Western Europe (45% to 51%) and North America (55% to 61%).
Video questionnaire
Table 2 summarises the findings in children aged 13–14 years
using the video questionnaire by region (the detailed findings
by centre and country are summarised in web table 2 available
online at http://thorax.bmj.com/supplemental) and fig 4 gives
the corresponding ranking plot. The mean prevalence of current
wheeze decreased slightly from 8.1% to 7.9%. However, the
changes in asthma prevalence showed different regional
patterns with current wheeze showing no change in Western
Europe but a marked decrease in Oceania (20.76% per year). It
also showed little change in the Eastern Mediterranean (20.05%
per year) and Latin America (20.04% per year), Western Europe
(0.00% per year) and Northern and Eastern Europe (0.03% per
year). There were increases in the Indian subcontinent (+0.32%
per year), Africa (+0.33% per year) and Asia-Pacific (+0.11% per
year), and a decrease in North America (20.26% per year). Thus,
the video questionnaire findings for current wheeze were
generally similar to those with the written questionnaire for
Africa, Oceania, Asia-Pacific, Western Europe and Eastern
Mediterranean. On the other hand, Latin America and Northern
and Eastern Europe showed an increase with the written
questionnaire but little change with the video questionnaire, the
Indian subcontinent showed little change with the written
questionnaire and an increase with the video questionnaire, and
North America showed an increase with the written questionnaire
but a decrease with the video questionnaire.
6–7 year age group
The changes in prevalence from phase I (with the phase III
prevalence rates in parentheses) in children aged 6–7 years are
summarised by region in table 1 (the detailed findings by centre
and country are summarised in web table 3 available online at
http://thorax.bmj.com/supplemental). The mean prevalence of
wheeze in the last 12 months (current wheeze) increased only
slightly from 11.1% to 11.6% (a mean increase of 0.13% per
year). There was also little change in the mean prevalence of
severe asthma. However, the changes in asthma symptom
prevalence showed different regional patterns with current
wheeze increasing in Western Europe (+0.20% per year) and
decreasing in Oceania (20.21% per year), both of which had
Table 1 Summary regional and global estimates for changes in the prevalence of self-reported asthma symptoms (written
questionnaire) between phase I and phase III: percentage change in symptom prevalence per year (and phase III symptom
prevalence percentage)
Centre
Phase I
(n)
Phase III
(n)
12 month prevalence
Ever had
asthma
Ever had
asthma and
current wheezeWheeze >4 Attacks
Wheeze
disturbs sleep
Severe wheeze
limiting speech
Exercise
wheeze Night cough
13–14-year-old children
Africa 28554 28397 0.16 (13.4) 0.06 (4.0) 0.05 (3.5) 0.02 (5.9) 0.44 (24.7) 0.91 (30.5) 0.07 (11.9) 20.01 (5.2)
Asia-Pacific 66222 57389 0.07 (8.8) 0.00 (2.3) 0.01 (0.7) 20.02 (2.1) 0.42 (17.0) 0.49 (20.6) 0.39 (12.6) 0.04 (4.0)
Eastern Mediterranean 16109 19887 20.10 (11.6) 20.04 (2.7) 20.04 (2.2) 20.05 (3.9) 20.11 (15.0) 0.22 (23.4) 0.11 (10.9) 0.00 (3.7)
Indian subcontinent 22120 20767 0.02 (6.4) 20.09 (2.1) 20.04 (1.1) 20.15 (2.6) 20.05 (6.9) 20.38 (20.0) 20.01 (6.1) 0.01 (3.1)
Latin America 46209 44550 0.32 (18.8) 0.02 (3.6) 20.01 (2.7) 20.02 (4.6) 0.13 (21.3) 0.83 (35.1) 0.25 (16.1) 0.12 (8.2)
North America 5863 4920 0.12 (21.5) 20.02 (4.9) 0.04 (3.1) 0.11 (7.0) 0.20 (24.9) 0.00 (21.1) 0.71 (22.5) 0.10 (13.2)
Northern and Eastern Europe 36508 32608 0.26 (11.6) 0.08 (2.3) 0.01 (0.8) 0.08 (2.2) 0.30 (14.3) 0.41 (14.0) 0.29 (5.9) 0.10 (2.5)
Oceania 15460 13317 20.39 (26.7) 20.38 (6.2) 20.05 (2.6) 20.21 (6.2) 20.29 (37.5) 20.01 (28.9) 0.93 (32.4) 0.16 (17.0)
Western Europe 85969 82844 20.07 (15.2) 20.05 (3.7) 20.02 (1.6) 20.02 (3.8) 0.03 (20.3) 0.64 (29.3) 0.33 (16.3) 0.07 (7.7)
Global total 323014 304679 0.06 (13.7) 20.02 (3.3) 20.01 (1.8) 20.01 (3.7) 0.15 (19.2) 0.51 (25.8) 0.28 (13.8) 0.06 (6.2)
6–7-year-old children
Africa 1696 2396 0.10 (5.6) 0.02 (2.8) 0.04 (2.3) 0.14 (4.8) 20.18 (5.4) 20.18 (8.0) 20.01 (3.3) 20.10 (1.1)
Asia-Pacific 40516 43403 20.06 (8.9) 20.09 (1.8) 20.04 (0.6) 20.04 (1.2) 20.10 (4.5) 0.47 (20.6) 0.12 (11.4) 20.04 (4.9)
Eastern Mediterranean 12853 13990 0.79 (11.7) 0.10 (2.3) 0.10 (2.3) 0.04 (1.9) 0.19 (4.9) 0.36 (15.7) 0.28 (9.1) 0.17 (4.6)
Indian subcontinent 16981 18877 0.06 (6.8) 20.07 (1.0) 20.06 (0.7) 20.09 (1.8) 20.04 (4.0) 20.17 (12.5) 20.05 (5.2) 0.02 (3.8)
Latin America 21467 21112 0.07 (21.4) 0.09 (5.0) 20.03 (3.6) 20.05 (4.9) 20.05 (10.3) 0.63 (34.4) 20.15 (13.2) 20.03 (9.0)
North America 5707 4014 0.32 (19.1) 0.01 (4.1) 0.04 (3.0) 0.04 (2.9) 0.22 (8.3) 0.34 (16.3) 0.74 (20.0) 0.37 (13.4)
Northern and Eastern Europe 24196 21984 0.05 (9.6) 0.04 (2.3) 0.00 (1.2) 0.02 (1.5) 0.06 (4.5) 0.33 (13.0) 0.23 (4.5) 0.13 (2.7)
Oceania 14233 13841 20.21 (21.8) 20.16 (7.0) 20.04 (3.0) 20.12 (3.6) 20.08 (15.1) 20.08 (28.4) 0.42 (29.2) 0.01 (16.8)
Western Europe 60100 53787 0.20 (9.7) 0.03 (2.1) 20.01 (1.5) 0.03 (1.7) 0.09 (4.6) 0.65 (20.7) 0.25 (9.1) 0.12 (4.5)
Global total 197749 193404 0.13 (11.6) 20.01 (2.7) 20.02 (1.6) 20.01 (2.1) 0.04 (6.0) 0.43 (20.4) 0.18 (10.8) 0.07 (5.7)
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previously shown high rates. Prevalence increased in Latin
America (+0.07% per year) which had also previously shown
relatively high rates, and in North America (+0.32% per year). It
also increased in the Eastern Mediterranean (+0.79% per year)
and Africa (+0.10% per year) which had previously shown some
of the lowest rates, while there was little change in Asia-Pacific
(20.06% per year), Northern and Eastern Europe (+0.05% per
year) or the Indian subcontinent (+0.06% per year). Thus, the
patterns in the 6–7 year age group were not completely
consistent with those in the 13–14 year age group. There were
increases in both age groups in Latin America, North America,
Northern and Eastern Europe and Africa, and decreases in both
age groups in Oceania. However, there were different patterns
in the two age groups in Western Europe and the Eastern
Mediterranean (decreases for 13–14-year-old children but
increases for 6–7-year-old children).
Figure 5 shows the ranking plot for children aged 6–7 years
showing the change in prevalence of current wheeze for each
centre by country, with countries ordered by their mean
prevalence (for all centres combined) across phase I and phase
III. As in the 13–14 year age group, it shows that in general the
countries with the highest prevalence in phase I (including
most of the English language countries) showed decreases in
prevalence between phase I and phase III, whereas some of the
countries which had previously had low prevalence showed
increases.
Figure 6 gives the corresponding ranking plot in children
aged 6–7 years for severe asthma, as measured by >4 attacks of
wheezing in the previous 12 months. It generally shows similar
patterns to those for current wheeze, with decreases in
prevalence in English language countries and increases in
prevalence in some, but not all, of the countries that had a low
prevalence in phase I.
As for the children in the 13–14 year age group, the
percentage of children aged 6–7 years reported to have had
asthma at some time in their lives increased between phase I
and phase III (table 1 and fig 7). There were particularly large
increases in Oceania (+0.42% per year), Western Europe
(+0.25% per year) and North America (+0.74% per year),
despite the fact that these regions showed little change (or even
a reduction) in symptom prevalence.
DISCUSSION
Phase I of ISAAC was a unique initiative involving genuinely
worldwide involvement in research into the patterns and causes
Figure 2 Ranking plot showing the change per year in prevalence of >4
attacks of wheezing in the previous 12 months in children aged 13–
14 years for each centre by country, with countries ordered by their
average prevalence (for all centres combined) across phase I and phase III.
The plot also shows the confidence interval about zero change for a given
level of prevalence (ie, the mean prevalence across phases I and III) given a
sample size of 3000 and no cluster sampling effect.
Figure 1 Ranking plot showing the change per year in prevalence of
current wheeze (wheeze in the past 12 months) in children aged 13–
14 years for each centre by country, with countries ordered by their mean
prevalence (for all centres combined) across phase I and phase III. The plot
also shows the confidence interval about zero change for a given level of
prevalence (ie, the mean prevalence across phases I and III) given a sample
size of 3000 and no cluster sampling effect.
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of asthma.3 It represented by far the most extensive interna-
tional survey of asthma symptom prevalence ever performed.5
The only other comparable international survey of asthma is
the European Community Respiratory Health Survey
(ECRHS)14 which studied adults (20–44 years) mainly from
European centres, and generally yielded similar findings to
those of ISAAC.15 The key findings included the high prevalence
of reported asthma symptoms in English language countries,
the high symptom prevalence in Latin America, the relatively
high prevalences in Western Europe but much lower preva-
lences in Eastern Europe with a clear Northwest-Southeast
gradient, and the relatively low prevalences in Africa and Asia
with the exception of the more affluent countries such as
Singapore and Japan.
The ISAAC phase I methodology was simple, the protocol
was rigorously applied, and a number of validation studies had
indicated that the ISAAC core questions on wheezing had
acceptable sensitivity and specificity when compared with other
indicators of asthma including physician diagnosis, other
questionnaires and physiological measures.10 Nevertheless, the
possibility could not be excluded that some of the patterns
observed could be due to issues of translation of terms such as
‘‘wheezing’’ or to differences in recognition and labelling of
symptoms.10 These issues are of less concern in the current
study since the focus is on time trends, and the same
methodology (including the same translations) has been used
in the same centres at different times.
Nevertheless, it is possible that recognition and labelling of
asthma symptoms may have shown different time trends in
different geographical regions, and may account in part for the
trends reported here. In this regard, it is of concern that some
regions showed different time trends with the written and
video questionnaires, although the differences were not
consistent: Latin America and Northern and Eastern Europe
showed an increase with the written questionnaire but little
change with the video questionnaire; the Indian subcontinent
showed little change with the written questionnaire and an
increase with the video questionnaire; and North America
showed an increase with the written questionnaire but a
decrease with the video questionnaire.
Increased use of effective treatment, especially inhaled
corticosteroids, is likely to have reduced asthma severity but
is unlikely to eliminate asthma symptoms completely, and is
therefore unlikely to explain the changes in prevalence.16 17
When assessing time trends in centres that had previously
shown high or low prevalences (figs 1–7), we avoided the
possibility of regression to the mean by using the mean
prevalence when assessing the change between phases I and
III,10 whereas a plot of changes relative to the phase I
Figure 4 Ranking plot showing the change per year in prevalence of
current wheeze (wheeze in the past 12 months) using the video
questionnaire in children aged 13–14 years for each centre by country,
with countries ordered by their mean prevalence (for all centres combined)
across phase I and phase III. The plot also shows the confidence interval
about zero change for a given level of prevalence (ie, the mean prevalence
across phases I and III) given a sample size of 3000 and no cluster
sampling effect.
Figure 3 Ranking plot showing the change per year in the lifetime
prevalence of asthma (‘‘asthma ever’’) in children aged 13–14 years for
each centre by country, with countries ordered by their mean prevalence
(for all centres combined) across phase I and phase III. The plot also shows
the confidence interval about zero change for a given level of prevalence
(ie, the mean prevalence across phases I and III) given a sample size of
3000 and no cluster sampling effect.
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prevalences would have shown spurious correlations even
when no such associations existed.11
Appropriate quality control measures are a critical compo-
nent of any multicentre research collaboration and this is
particularly true of ISAAC, given the unique global scope of the
collaboration and the wide variation in the research experience
of the collaborators. The extensive quality control measures
adopted for ISAAC phase III are described in detail elsewhere,2
but the possibility that inappropriate implementation of the
study design may have introduced bias in the results from
individual centres should be acknowledged. However, it is
extremely unlikely that any such bias would affect the broader
regional and global patterns presented in this publication.
It should also be stressed that prevalence and time trend data
such as this primarily serve for purposes of hypothesis generation
rather than hypothesis testing. Furthermore, with more than 100
Figure 6 Ranking plot showing the change per year in prevalence of >4
attacks of wheezing in the previous 12 months in children aged 6–7 years
for each centre by country, with countries ordered by their mean
prevalence (for all centres combined) across phase I and phase III. The plot
also shows the confidence interval about zero change for a given level of
prevalence (ie, the mean prevalence across phases I and III) given a sample
size of 3000 and no cluster sampling effect.
Figure 5 Ranking plot showing the change per year in the prevalence of
current wheeze (wheeze in the past 12 months) in children aged 6–7 years
for each centre by country, with countries ordered by their mean
prevalence (for all centres combined) across phase I and phase III. The plot
also shows the confidence interval about zero change for a given level of
prevalence (ie, the mean prevalence across phases I and III) given a sample
size of 3000 and no cluster sampling effect.
Table 2 Summary regional and global changes in the prevalence of self-reported asthma symptoms (video questionnaire) between
phase I and phase III in 13–14-year-old children: percentage change in symptom prevalence per year (and phase III symptom
prevalence perentage)
Centre
Phase I
(n)
Phase III
(n) Current wheeze Exercise wheeze Night wheeze Night cough Severe wheeze
Africa 14465 11467 0.33 (11.0) 0.23 (14.6) 0.16 (6.2) 0.67 (19.7) 0.29 (7.7)
Asia-Pacific 53679 51196 0.11 (6.8) 0.25 (10.7) 0.02 (2.0) 0.30 (10.4) 0.05 (3.5)
Eastern Mediterranean 6031 8851 20.05 (6.3) 0.06 (8.8) 20.03 (3.1) 0.08 (8.8) 20.04 (3.2)
Indian subcontinent 12562 11552 0.32 (7.3) 0.15 (4.8) 0.30 (4.9) 0.18 (4.8) 0.00 (3.1)
Latin America 18003 18599 20.04 (11.9) 20.10 (14.2) 0.00 (4.5) 0.74 (20.6) 0.01 (6.5)
North America 5673 4895 20.26 (11.3) 20.80 (18.6) 20.11 (8.3) 0.62 (17.7) 20.44 (7.2)
Northern and Eastern Europe 13970 13167 0.03 (2.7) 0.15 (6.3) 0.02 (1.6) 0.23 (7.5) 0.06 (1.7)
Oceania 15408 13205 20.76 (11.2) 21.64 (15.9) 20.73 (5.1) 20.32 (19.4) 20.56 (7.4)
Western Europe 33722 34581 0.00 (7.3) 21.24 (13.2) 20.18 (3.1) 0.23 (16.0) 0.07 (4.4)
Global total 173513 167513 0.00 (7.9) 20.21 (11.6) 20.04 (3.4) 0.25 (13.6) 0.02 (4.5)
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centres involved, it is to be expected that at least five centres
would show statistically significant changes by chance alone. It is
therefore more valuable to focus on the regional and global
patterns and trends than on the findings in individual centres.
Bearing these reservations in mind, the findings reported
here are of considerable interest. First, they show that in most
high prevalence countries, particularly the English language
countries, the rise in the prevalence of asthma symptoms has
peaked and may even have begun to decline. This is consistent
with the findings of other recent studies in children18–24 and in
adults.25 26 There are some exceptions to this trend but, of the
European and English language countries which showed a
relatively high prevalence in phase I, only Germany27 and
Finland have shown significant increases in symptom pre-
valence in phase III. The increases for North America are due to
increases in Barbados (where the phase I data were too late for
inclusion in the phase I paper5); the one US centre showed a
small decline in symptom prevalence consistent with the
findings for other English language countries.
Second, a number of countries that had high or intermediate
levels of symptom prevalence in phase I have shown significant
increases in prevalence in phase III; these include Latin
American countries such as Costa Rica, Panama, Mexico,
Argentina and Chile, and Eastern European countries such as
the Ukraine and Romania. Other countries to show significant
increases in symptom prevalence included Barbados, Tunisia,
Morocco and Algeria.
Third, with the exception of India, all of the countries with
very low symptom prevalence rates in phase I reported
increases in prevalence in phase III, although only the increases
for Indonesia and China were statistically significant.
Finally, virtually all countries—irrespective of the level of
symptom prevalence—reported increases in lifetime asthma
prevalence between phases I and III. In fact, the increases were
most marked in those countries with the highest mean
prevalence between phase I and phase III (figs 3 and 7),
despite the fact that many of these countries reported declines
in the prevalence of asthma symptoms between phase I and
phase III (figs 1 and 4).
So what do these findings mean? Perhaps the most striking
finding is the apparent decline in symptom prevalence in
English language countries. Just as we do not (yet) know why
prevalence has increased since the 1950s, we do not know why
it should now be decreasing.16 The ‘‘hygiene hypothesis’’ has
been proposed as one explanation for the increases in symptom
prevalence, although it does not appear entirely to account for
the time trends since the increases have occurred for both non-
atopic (non-eosinophilic) and atopic (eosinophilic) asthma,
whereas the hygiene hypothesis would only explain (at most)
trends for atopic asthma.28 Furthermore, it does not seem
apparent that the English language countries have become
‘‘less hygienic’’ in recent decades, although increases in infant
and childhood infections could have occurred due to specific
factors such as increased use of childcare facilities.29 The
hygiene hypothesis is also unlikely to explain the considerably
higher prevalences in many Latin American countries than in
Spain and Portugal which are more consistent with changes in
environmental exposures other than hygiene.30–32
Other ‘‘established’’ asthma risk factors do not appear to
explain the worldwide asthma prevalence patterns33–42 or time
trends, particularly the decline in English language countries. It
also seems unlikely that the decline in symptom prevalence is
due to decreased recognition and labelling of asthma symp-
toms, given that the prevalence of ‘‘asthma ever’’ has increased.
For example, Garcı´a-Marcos et al43 argue that asthma is now
considered a less stigmatising disease than it was at the time of
phase I, and the word ‘‘asthma’’ is more readily accepted. This
could explain why, in some countries, symptom prevalence has
not increased or has even declined, but the prevalence of
‘‘asthma ever’’ has increased. This has occurred particularly in
English language countries and may also in part reflect
international differences in healthcare systems, as well as more
specific differences in asthma recognition and diagnosis. It
should also be noted that the findings for ‘‘asthma ever’’ are to
some extent reassuring with regard to the findings for current
asthma symptoms, since they indicate that an increased
recognition and diagnosis of asthma has not been accompanied
by an increase in reporting of asthma symptoms; such an
increase would have been expected if the symptom prevalence
patterns were entirely due to differences in recognition and
labelling of symptoms.
These findings for English language countries and Western
Europe are intriguing and to some extent reassuring, but they
should not be taken to indicate that the global ‘‘pandemic’’ of
asthma is easing and that the worst is over. The phase III
findings show striking increases for Latin American countries
to the extent that, in future, we may be describing asthma as a
‘‘Spanish and Portuguese speaking’’ rather than an ‘‘English
speaking’’ disease. The modest increases for China are of
potentially major significance given the size of China’s
population and its rapid economic growth. Furthermore, there
are some intriguing patterns with, for example, decreases in
prevalence in India but modest increases in China, Indonesia,
Taiwan and South Korea, and stronger increases in Morocco,
Figure 7 Ranking plot showing the change per year in the lifetime
prevalence of asthma (‘‘asthma ever’’) in children aged 6–7 years for each
centre by country, with countries ordered by their mean prevalence (for all
centres combined) across phase I and phase III. The plot also shows the
confidence interval about zero change for a given level of prevalence (ie,
the mean prevalence across phases I and III) given a sample size of 3000
and no cluster sampling effect.
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Algeria and Tunisia. As with the phase I findings, it is to be
hoped that this new evidence on time trends will lead to further
questioning and testing of current theories, and the develop-
ment of new theories of asthma aetiology. In addition, these
findings suggest that, although asthma symptom prevalence is
no longer increasing in most English language and Western
European countries, its global burden may continue to rise.
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